Human Serum Albumin/interferon alpha2b fusion protein vs peginterferon alfa-2a (Pegasys)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Hepatitis B
Shared mechanism: Type I interferon receptor · full Chronic Hepatitis B pipeline
Human Serum Albumin/interferon alpha2b fusion protein
Developed by Tianjin SinoBiotech
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
peginterferon alfa-2a (Pegasys)
Marketed by pharmaand and partners
NCT01519960 · Phase 3 · completed
This open-label, randomised trial compared 48 weeks of peginterferon alfa-2a with untreated observation in children with HBeAg-positive chronic hepatitis B without advanced fibrosis (101 vs 50 randomised). The primary endpoint, HBeAg seroconversion 24 weeks after the end of treatment, is a laboratory measure that knowledge of treatment assignment cannot change. Seroconversion occurred in 25.7% of treated children vs 6% of controls (odds ratio 5.43, 95% CI 1.54 to 19.2; p=0.0043), so the primary endpoint was met. The absence of blinding and of a placebo limits the strength of this evidence.
Next expected readout: April 2027 · NCT07389044 (registry estimate)
Reported efficacy
Percentage of Participants With HBeAg Seroconversion at 24 Weeks After End of Treatment (EOT)/POP in Groups A and B (FU Week 24 (up to 72 weeks overall)): Percentage of Participants With HBeAg Seroconversion at 24 Weeks After End of Treatment (EOT)/POP in Groups A and B (FU Week 24 (up to 72 weeks overall)): Group A: PEG-IFN Monotherapy Without Advanced Fibrosis 25.7 percentage of participants (95% CI 17.56 to 35.4) | Group B: Untreated Control Without Advanced Fibrosis 6 percentage of participants (95% CI 1.25 to 16.55) (met)
Result source: NCT01519960
Results for Chronic Hepatitis B
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Human Serum Albumin/interferon alpha2b fusion protein: no structured comparison results are available for Chronic Hepatitis B.
peginterferon alfa-2a (Pegasys): registry results are on file for Chronic Hepatitis B, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Human Serum Albumin/interferon alpha2b fusion protein's landscape · peginterferon alfa-2a (Pegasys)'s landscape